June 22, 2004

Neurochem to present at the second annual "TSX Canada Day in New York City" event.

- Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on June 23, 2004, Dr. Francesco Bellini, Chairman and CEO of Neurochem, will present an overview of the Company and its product pipeline at the second annual "TSX Canada Day in New York City" event to be held at the Millennium Broadway Hotel in New York. The presentation will take place from 10:20 to 10:50 AM EDT. The purpose of the event is to allow attendees to learn about senior market investment opportunities in Canadian Capital markets. The corporate presentation will be available on the Company's Web site at:
http://www.neurochem.com/Investor.htm#Presentation .

A webcast of Neurochem's presentation can also be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=nrm.to&item_id=910512 . This webcast will be available for 30 days through to July 23, 2004.

About Neurochem

Neurochem is focused on the development and commercialization of innovative therapeutics for neurological disorders. The Company's pipeline of proprietary, disease-modifying, oral products addresses critical, unmet medical needs. Fibrillex™, designated as an orphan drug and as a Fast Track Product candidate, is in a Phase II/III clinical trial for the treatment of Amyloid A Amyloidosis. Alzhemed™, for the treatment of Alzheimer's Disease, is in a Phase III clinical trial and Cerebril™, for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy has completed a Phase II clinical trial.
For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1 877 680-4500 or visit our website at: (www.neurochem.com).

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation as well as other risks included in public filings of Neurochem. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance on the forward-looking statements included in this news release. These statements speak only as of the date made and Neurochem is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise.

For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com

275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.